Battle Stocks: Procter & Gamble vs. Unilever vs. Colgate-Palmolive

The Staples Battle

This is the tenth installment of Battle Stocks, the weekly head-to-head series from Wealth Engine Pro Insights, and it closes out the opening run of the series. It is also the natural companion to an earlier battle: Coca-Cola vs. PepsiCo. There we pitted two beverage giants against each other. Here we widen the lens to the cabinet under the sink, the shower shelf, and the laundry room: three consumer conglomerates whose brands are so embedded in daily life that most people use one of their products before breakfast without thinking about it.

The backdrop matters. For most of 2026, the market has rewarded growth and punished defense. The AI trade pulled capital toward chips, power, and data centers, and the steady compounders of the consumer-staples aisle were treated as dead money. P&G, Unilever, and Colgate all sit below their 52-week highs. The consumer itself has split into what P&G's own CEO calls a "K-shaped" economy, where higher-income households keep spending while lower-income ones trade down to private label. None of that is a reason to ignore these companies. It is a reason to look closely at which one is actually the best business, because when the cycle turns, quality in staples tends to reassert itself.

We picked the three most distinct versions of the same idea. Procter & Gamble (PG) is the premium operator: the largest, the best-run, and the most expensive. Unilever (UL) is the transformation story: cheaper, higher-yielding, and fresh off a portfolio overhaul that spun out its ice cream business. And Colgate-Palmolive (CL) is the focused specialist: the smallest, with the single most dominant brand position of the three and a balance sheet that demands a closer look. All three are Dividend aristocrats or kings. Only one of them is the business the data actually ranks first.

The Tale of the Tape

The first thing the tape shows is scale. Procter & Gamble is more than two and a half times the market value of Unilever and nearly five times Colgate, and it generates more annual revenue than the other two combined. The second thing it shows is that price and quality do not line up neatly. Unilever is the cheapest on a forward earnings basis and pays the highest yield. Colgate has the fattest gross margin of the three by a wide margin, yet trades at a premium multiple on the slowest growth. And P&G sits in the middle on yield while commanding the richest strength-adjusted valuation.

The numbers in this table describe what each company looks like today. They do not, on their own, tell you which business is built to keep winning. For that we have to go one level deeper: into the brands, the margins, the balance sheets, and finally the systematic scores. That is where the three start to separate.

The Procter & Gamble Case

Procter & Gamble is the closest thing the consumer-staples world has to a blue-chip standard. At roughly $347 billion in market value and about $84 billion in fiscal 2025 sales, it is the largest of the three by a wide margin, and it has earned that position with a portfolio of daily-use essentials that need no introduction: Tide, Pampers, Gillette, Bounty, Charmin, Crest, Dawn, Olay, and Pantene among them. A decade ago the company shed around 100 brands to concentrate on its strongest franchises, and that discipline shows up in the results.

The recent numbers are steady rather than spectacular, which is exactly what you want from the anchor of a defensive portfolio. In its fiscal third quarter, reported in April, P&G posted net sales of $21.2 billion, up 7%, with organic sales up 3% and volume growing for the first time in a year. Core earnings per share came in at $1.59. Management held its full-year core EPS guidance of $6.83 to $7.09, a roughly 2% increase at the midpoint, and reaffirmed a plan to return about $15 billion to shareholders this fiscal year, split between roughly $10 billion in dividends and $5 billion in buybacks.

The dividend is the headline. P&G has raised its payout for 70 consecutive years and has paid one for 135 years running, putting it among the most reliable income stocks in existence. The yield sits near 2.9%, covered comfortably by earnings and cash flow. Underneath that, the quality markers are strong: gross margins around 50%, interest coverage above 25x, and free cash flow productivity north of 100%. This is a business that converts sales into cash with unusual consistency and returns most of it to owners. The case for P&G is not that it is cheap or fast. It is that it is the best-run franchise in the group, and it behaves like one.

The Unilever Case

Unilever is the most interesting story of the three, and the cheapest stock. At roughly $132 billion in market value with about EUR 50.5 billion (around $55 billion) in continuing turnover, it owns a sprawling stable of brands spanning Dove, Hellmann's, Knorr, Vaseline, Rexona, and Axe. For years the knock on Unilever was that it was a conglomerate trying to do too much at once. Over the past two years management has set out to fix exactly that.

The centerpiece was the demerger of the ice cream business, completed in December 2025, which spun Magnum, Ben & Jerry's, and Wall's into a separate, publicly listed company called The Magnum Ice Cream Company. Unilever booked a roughly EUR 3.4 billion gain and retained a 19.9% stake to sell down over time. Ice cream had a different supply chain, lower margins, and seasonal swings that did not fit the rest of the portfolio, so removing it leaves a simpler, structurally higher-margin company focused on Beauty & Wellbeing, Personal Care, Home Care, and Foods.

The 2025 results showed the early payoff. Underlying sales grew 3.5% for the year and accelerated to 4.2% in the fourth quarter. Underlying operating margin expanded 60 basis points to 20.0%, and free cash flow was a strong EUR 5.9 billion. The company's Power Brands, which make up 78% of turnover, grew 4.3%. Unilever returned roughly EUR 6.0 billion to shareholders and approved a new buyback of up to EUR 1.5 billion. Under CEO Fernando Fernandez it has kept reshaping the portfolio with bolt-on deals (Dr. Squatch, Wild, Minimalist) and is now exploring a bid for the supplements maker Thorne while floating plans to separate its food brands as well. The stock trades around 17 to 18 times forward earnings, the lowest of the three, and yields about 3.6%, the highest. The narrative here is genuinely the best of the group. Whether the underlying business has caught up to the narrative is the question the scores will press on.

The Colgate Case

Colgate-Palmolive is the smallest and most focused of the three, and it owns the single most dominant brand position in this battle. At roughly $73 billion in market value on $20.38 billion in 2025 sales, Colgate is a fraction of P&G's size, but in its core category it is the undisputed leader: its global toothpaste market share sits at 41.3%, and its share of manual toothbrushes is 32.4%. Add the Hill's Science Diet pet nutrition business, and you have a company built around a handful of categories it dominates rather than a broad portfolio it merely participates in.

That focus produces the best gross margin in the group, around 60%, and operating margins near 22%. The dividend record is elite: Colgate has increased its payout for 63 consecutive years and has paid one without interruption since 1895. The stock is also one of the lowest-beta names in the market, near 0.3, which is why it is a perennial holding in conservative income portfolios.

The complications are growth and the balance sheet. Full-year 2025 organic sales grew only about 2%, and management narrowed guidance to a 1% to 2% range, leaning on pricing rather than volume. GAAP earnings per share fell 25% to $2.63, dragged down by a goodwill and intangible-asset impairment tied to the skin-health business it acquired. There was a genuine bright spot early in 2026: first-quarter net sales reaccelerated to +8.4%, helped by foreign exchange swinging from headwind to tailwind, and the company reaffirmed its guidance and laid out a new 2030 growth strategy. That reacceleration is real and it is part of why the platform's forward outlook on Colgate is the most positive of the three. The catch, which we get to next, is how Colgate finances itself.

Moats and Margins

All three companies share the same fundamental moat: decades of brand equity, enormous distribution scale, and the simple habit loop of products people buy again and again without comparison shopping. Shelf space at a major retailer is hard to win and harder to keep, and all three have it. But the moats are not identical in shape, and the differences matter.

P&G's edge is breadth and balance. It is a leader across ten categories rather than one, which smooths the impact when any single business slows, and its scale funds an innovation and marketing engine that smaller rivals struggle to match. Colgate's edge is depth: nobody on earth sells more toothpaste, and that category leadership produces the highest gross margin in the group. But depth is also concentration, and Colgate's skin-health write-down is a reminder that its forays outside the core have not always worked. Unilever's edge is reach, particularly in emerging markets and in fast-growing beauty and wellness, which is both an opportunity and a source of currency and execution risk.

The margin picture is revealing. Colgate has the highest gross margin (~60%) but P&G converts to the best operating margin (~24%), evidence of P&G's cost discipline across a much larger base. Unilever sits lowest on both (46.9% gross, 20.0% operating underlying), with management betting that the post-ice cream portfolio lifts those numbers over time.

The real separator is the balance sheet, and it points in P&G's favor in a way that becomes important in the next section. Procter & Gamble carries a debt-to-equity ratio around 1.5. Colgate, by contrast, has bought back so much of its own stock over the decades that its book equity has been driven down to near zero, pushing its debt-to-equity ratio above 8. That is a deliberate capital-efficiency strategy that boosts return on equity, but it also leaves little balance-sheet cushion and, as we are about to see, it breaks one of the platform's valuation models entirely.

What the Wealth Engine Scores Say

Before the editorial verdict, here is what the Wealth Engine Pro platform's systematic scoring shows for all three stocks right now. These scores are backward-looking by design: they grade what a company is today based on reported financials, not what the story says it might become.

The scores broadly confirm the quality ranking. Procter & Gamble is the only one of the three rated Strong, and it leads on every component that measures business quality: the highest Financial Health (74), the widest Moat (12/15), and the best Growth score (8.5/15). The price of that quality is the only knock against it. The platform flags PG as Expensive, about 33% above its calculated fair value. Unilever lands at the bottom on Company Strength and Growth, which is the systematic way of saying the fundamentals have not yet caught up to the transformation story. Colgate sits in the middle on strength but carries the most positive forward Outlook, consistent with its early-2026 reacceleration.

Two of the fair-value readings need a caveat, and we would rather show the data and explain it than hide it. Colgate's blended fair-value model returns a figure so far above the current price that it is not usable. The cause is the negative book equity described above: when shareholder equity is near zero or negative, the asset-based and earnings-power components of the model break down and produce an artificially large "deep value" result. It is a modeling artifact, not a real signal. On ordinary earnings multiples, Colgate trades around 21 times forward earnings (and a GAAP multiple in the low 30s, distorted by the impairment), which is roughly fair to slightly rich for its growth rate, not a bargain. Unilever's fair value carries a smaller caveat: it is a euro-denominated business measured through a U.S. ADR, so the conversion adds noise, but the modest premium the model shows is directionally reasonable.

These scores are systematic. They evaluate companies based on reported financials, balance sheet quality, moat characteristics, and valuation models. They measure what a company is today, not what it might become, which is the entire point. This article is doing something different: weighing which of three durable franchises is built to keep compounding through a full cycle, and which premium is actually worth paying. Both perspectives are real data. The platform tells you P&G is the strongest business and the priciest, that Unilever is the cheapest and the weakest on current fundamentals, and that Colgate is a dominant niche player with a balance sheet that resists tidy valuation. Research any of these stocks yourself on the platform and decide which signal matters most for your situation.

The Valuation Verdict

Valuation is where the three businesses ask very different questions of an investor.

Procter & Gamble trades at roughly 22 times forward earnings and yields about 2.9%. The platform calls it Expensive, around 33% above fair value, and that is the honest tension in the P&G case: you are paying a full price for the best-run business in the group. The bet is that quality this consistent, with 70 years of dividend growth and a cash machine behind it, is worth a premium and tends to justify it over time. The question PG asks is whether you are willing to pay up for durability.

Unilever is the cheapest of the three at about 17 to 18 times forward earnings, with the highest yield near 3.6%. On the surface that is the value pick. But the platform rates it the weakest business of the three on current fundamentals, with the lowest Growth score. So the question Unilever asks is sharper than it looks: is the discount an opportunity, because the market has not yet priced in a real turnaround, or is it a value trap, because the stock is cheap for the same reason the scores are soft? The transformation is promising, but it is still a story the reported numbers have not fully confirmed.

Colgate is the most paradoxical. It trades around 21 times forward earnings, a near-premium multiple, on the slowest organic growth of the three, and it pays the lowest yield at about 2.4%. Strip out the broken fair-value model and the plain reading is that Colgate is priced like a steady compounder while growing in the low single digits. Its dominant moat and recent reacceleration support that premium to a point; its growth rate and leverage argue it is close to fully valued. The question Colgate asks is whether a great brand at a full price, financed with a thin balance sheet, is worth owning over cheaper or higher-quality alternatives.

What Could Go Wrong

Risks for Procter & Gamble

A premium price on slow growth. P&G's organic sales were flat in the second fiscal quarter before reaccelerating, and at 22 times forward earnings the stock leaves little room for a stumble. A bear case exists, and it is straightforward: a richly valued staple growing in the low single digits, with margins under pressure, does not need much to disappoint.

Input costs and geopolitics. Management has warned that if Brent crude holds near $100 a barrel, the company faces an annual after-tax headwind of roughly $1 billion, and it flagged uncertainty tied to Middle East conflict. A weak Chinese consumer, which affects nearly a fifth of P&G's beauty sales, is a separate drag that could persist.

Risks for Unilever

The turnaround is unproven. The strongest argument against Unilever is the platform's own Growth score of 3 out of 15. The story of a simpler, faster company is attractive, but the systematic data says the fundamentals are still the weakest of the three. If the post-demerger momentum fades, the cheap multiple is cheap for a reason.

Emerging-market and currency exposure, plus constant surgery. Reported turnover fell in 2025 largely on currency, and Unilever carries real exposure to volatile and hyperinflationary markets. Meanwhile the portfolio is in perpetual motion, with a food-brand separation now on the table. Serial restructuring can unlock value, but it also creates stranded costs and management distraction.

Risks for Colgate

A thin balance sheet and slow growth. Negative book equity and a debt-to-equity ratio above 8 leave Colgate with less financial flexibility than its peers and make it more sensitive to interest rates. Pair that with organic growth guided to just 1% to 2% and a recent impairment, and the margin for error is narrow.

The honest counterpoint. In fairness to Colgate, the bull case is real. First-quarter 2026 net sales reaccelerated 8.4%, the company holds the most dominant single brand position in this battle, its beta of 0.3 makes it a genuine ballast in a downturn, and the platform's forward Outlook is the most positive of the three. The leverage that looks risky on paper is also a deliberate choice that lifts return on equity. A reader who weighs momentum and downside protection more heavily than balance-sheet conservatism could reasonably land on Colgate.

The Data Picks a Winner

Three durable franchises, three legitimate cases, and one that the data ranks first. The winner of this battle is Procter & Gamble.

The reasoning is not complicated, and it follows the numbers rather than the narrative. On every systematic measure of business quality, P&G leads. It is the only one of the three rated Strong. It posts the highest Financial Health score (74), the widest Moat (12/15), and the best Growth score (8.5/15). It converts the largest revenue base in the group into the best operating margin, it carries the most conservative balance sheet of the three by a wide distance, and it has raised its dividend for 70 straight years while returning roughly $15 billion to owners annually. When you ask which of these companies is the highest-quality business as it actually exists today, the answer is not close.

The honest counterarguments are exactly the two other cases. Unilever is cheaper and yields more. Colgate has the best near-term momentum and the most dominant single brand. Both are worth taking seriously, and both fall short of P&G on the measure that matters most for a long-term staple.

Unilever's discount is the cleanest illustration of why we lead with data over narrative. The transformation story is the best in the group, but the platform rates Unilever the weakest business of the three on current fundamentals, with the lowest Growth score. The stock is cheap, and the systematic data suggests it is cheap for a reason. Buying the most compelling story at the lowest price only works if the story shows up in the financials, and it has not done so yet. Colgate is the more serious challenger. Its moat is real and its early-2026 reacceleration is encouraging. But it is the slowest grower of the three, it is priced like a compounder it is not quite, and it is financed with a balance sheet so thin that it breaks the valuation model. A dominant brand at a full price on a fragile balance sheet is a fine business, but it is not the best business here.

P&G is the rare staple that is both the highest quality and the one whose premium the systematic scores actually justify. The obvious objection is price: the platform flags it as Expensive, about 33% above fair value, so the entry point matters and this is a judgment about business quality rather than a call on the next few months. But in consumer staples, paying up for the best operator has historically been the durable trade. The cheapest name is not always the best value, and the best story is not always the best business.

At Wealth Engine Pro, we follow the numbers, not the narrative. The narrative says buy the cheapest staple, and that points to Unilever. The narrative says buy the momentum, and that points to Colgate. The numbers say the strongest, widest-moat, best-run franchise of the three is Procter & Gamble, and quality in staples compounds. When the story and the data tell different versions of which company to own, the data usually wins. In this battle, the data picks Procter & Gamble.

What Battle Do You Want to See Next?

This installment closes the opening run of Battle Stocks, a weekly series that has put chipmakers, beverage giants, power producers, banks, and now consumer conglomerates head to head. The series continues, and we want you to pick the fights. Tell us on social media or reply to our newsletter with the matchup you want to see next, whether that is two pharma giants, the semiconductor equipment names, or the retailers fighting for the same shopper. The best suggestion becomes a future installment.